Cytocom statera

WebJan 24, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers ... WebOct 5, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers...

Investor Relations - Statera Biopharma, Inc

WebUNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 WebAug 31, 2024 · Cytocom, Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications (732) 754-2545 [email protected] Tiberend Strategic Advisors, Inc. Maureen McEnroe, CFA (Investors) (212) 375-2664 [email protected] Johanna Bennett (Media) (212) 375-2686 [email protected] fitbit charge 4 rebel https://pckitchen.net

Cleveland Bio gains after filing Form S-4 for Cytocom deal

WebApr 10, 2024 · Subsequent to the merger, CBLI adopted a new corporate name, "Statera BioPharma, Inc.", with the ticker symbol "STAB," effective on September 1, 2024 ("Statera"). Statera emerged as a publicly ... WebSep 28, 2024 · Cytocom issued the 125,000 shares of its common stock on March 4, 2024. Due to the fact that Cytocom did not have sufficient funds by January 25, 2024, it was unable to meet its payment obligations to Ira Gaines and the Gaines Trust due on that date. The $50,000 payment was made on June 9, 2024. WebOct 5, 2024 · Statera Biopharma is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T cells and antibodies, thereby activating essential... can flash teleport

Cytocom, Inc. Announces Plan to Adopt New Corporate Name …

Category:Statera Biopharma Receives Positive Nasdaq Listing Determination

Tags:Cytocom statera

Cytocom statera

Cytocom, Inc. completed the acquisition of Cleveland BioLabs, Inc.

WebOct 27, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers... WebFeb 18, 2024 · Feb. 18, 2024 1:14 AM ET Statera Biopharma, Inc. (STAB) STAB By: ... (CBLI)soars 27%after-hours after filing Form S-4 with the SEC in connection with its merger agreement with Cytocom

Cytocom statera

Did you know?

WebAug 5, 2024 · Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby … WebSep 8, 2024 · According to the company, “Statera set aside a certain number of the total shares issuable in the Cytocom-Cleveland BioLabs merger to ensure that the former ImQuest Life Sciences stockholders...

WebSep 7, 2024 · Cytocom acquired ImQuest Life Science, Inc. in an all-stock deal on June 23, 2024, and provided an update on its integration on September 1. Together, these entities will strengthen and expand... WebSep 8, 2024 · Statera is currently developing therapies designed to directly interact with antigen-specific killer T-cells and antibodies, which will then activate essential immune …

WebCYTO-200 program therapies, are noroxymorphone analogs developed by discovering the anti-angiogenic and anti-inflammatory properties of naltrexone, yielding a new way of fighting cancer, inflammatory, … WebOct 6, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers ...

WebApr 10, 2024 · In 2024, Cytocom, announced the completion of its merger with CBLI which resulted in our receipt of 1,150,000 common shares of CBLI, reflecting our retained minority interest in Cytocom. Subsequent to the merger, CBLI adopted a new corporate name, "Statera BioPharma, Inc.", with the ticker symbol "STAB," effective on September 1, …

WebFeb 20, 2015 · VA Directive 6518 4 f. The VA shall identify and designate as “common” all information that is used across multiple Administrations and staff offices to serve VA … fitbit charge 4 recoveryWeb--Cytocom, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to … fitbit charge 4 purple bandWebStatera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2024, Cleveland BioLabs merged with Cytocom, … can flash run on waterWebMay 13, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers ... fitbit charge 4 pricesWebApr 27, 2024 · FORT COLLINS, Colo., April 27, 2024 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus... can flash travel faster than lightWebStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, … fitbit charge 4 rebootWebAug 31, 2024 · Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby … fitbit charge 4 pushing stroller